Waldencast (WALD) Chief Growth Officer Sebti Hind Sells 193,816 RSUs

What Happened Sebti Hind, Chief Growth Officer and a director of Waldencast plc (WALD), had 193,816 restricted stock units (RSUs) repurchased by the issuer on July 30, 2026. The RSUs were bought by Waldencast at $2.00 per RSU for total proceeds of $387,632. The filing reports the disposition as a derivative transaction (code D) — this was an issuer purchase of outstanding RSUs rather than an open-market sale of shares.

Key Details

• Transaction date and price: July 30, 2026 — 193,816 RSUs at $2.00 each; total $387,632.
• Transaction type: Derivative disposition (issuer repurchase of RSUs), Form 4 code D.
• Shares owned after transaction: Not specified in the filing.
• Filing date: August 7, 2026 (filed 8 days after the transaction); Form 4s are typically due within two business days, so this filing occurred after that window.
• Relevant footnotes:
  • F1: Each RSU represents a contingent right to one Class A ordinary share or equivalent cash at the plan administrator’s election.
  • F2: The repurchase was in connection with Waldencast’s sale of its Obagi Medical business on July 30, 2026; effective that date, Hind transitioned to lead Obagi Medical.
  • F3: The RSUs originated from an October 30, 2024 grant of 290,723 RSUs that would have vested in three annual tranches (Oct 1, 2025; Oct 1, 2026; Oct 1, 2027).

Context This was not an open-market sale of existing shares but an issuer buyout of RSUs related to the company’s divestiture of Obagi Medical; the repurchase resulted in cash payment to the reporting person. Such derivative/treatment transactions reflect contractual or corporate-event-driven settlements rather than a straightforward insider sale indicating personal trading sentiment.